Core Points - LAVA Therapeutics announced that approximately 87% of its outstanding common shares were validly tendered in the tender offer by XOMA Royalty Corporation, satisfying the minimum tender condition [1] - The subsequent offering period for LAVA shareholders to tender their shares will expire on November 20, 2025, and shares tendered during this period cannot be withdrawn [2] - LAVA intends to voluntarily delist its common shares from Nasdaq, contingent upon the completion of the acquisition by XOMA Royalty [3] Company Overview - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships with Johnson & Johnson and Pfizer for specific cancer treatments [4]